Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Non-Current Deferred Tax Liability of $390733.0 for Q1 2026, down 48.7% year-over-year from $761737.0 in Q1 2025, and down 8.18% quarter-over-quarter from $425527.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $390733.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 48.7% year-over-year to $390733.0; the TTM figure through Mar 2026 stood at $390733.0 (down 48.7% YoY), while the FY2025 annual figure was $495113.0, down 48.62% from the prior year.
- Non-Current Deferred Tax Liability eased to $390733.0 in Q1 2026 per NEUP's latest filing, from $425527.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.3 million in Q2 2022 and bottomed at $390733.0 in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $756589.6 across 5 years, with a median of $796530.5 in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability declined 9.19% — and 2025, when it tumbled 49.52%.
- Neuphoria Therapeutics' Non-Current Deferred Tax Liability stood at $1.3 million in 2022, then decreased by 14.12% to $1.1 million in 2023, then retreated by 23.81% to $842921.0 in 2024, then sank by 49.52% to $425527.0 in 2025, then declined by 8.18% to $390733.0 in 2026.
- Business Quant data shows NEUP's Non-Current Deferred Tax Liability at $390733.0 in Q1 2026, $425527.0 in Q4 2025, and $460320.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 390,733.00 |
| Mar 31, 2026 | 390,733.00 |
| Dec 31, 2025 | 425,527.00 |
| Dec 31, 2025 | 425,527.00 |
| Sep 30, 2025 | 460,320.00 |
| Sep 30, 2025 | 460,320.00 |
| Jun 30, 2025 | 495,113.00 |
| Jun 30, 2025 | 495,113.00 |
| Mar 31, 2025 | 761,737.00 |
| Mar 31, 2025 | 761,737.00 |
| Dec 31, 2024 | 842,921.00 |
| Dec 31, 2024 | 842,921.00 |
| Sep 30, 2024 | 831,324.00 |
| Sep 30, 2024 | 831,324.00 |
| Jun 30, 2024 | 963,540.00 |
| Jun 30, 2024 | 963,540.00 |
| Jun 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.29 Mn |